Journal of Neurology Neurosurgery and Psychiatry

Papers
(The H4-Index of Journal of Neurology Neurosurgery and Psychiatry is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
091 The East London Parkinson’s disease project – engaging a diverse population in research135
175 A case series of anti-HMGCR immune mediated necrotizing myopathy: the West Midlands data118
102 Levodopa and melanoma what do clinicians think?103
117 Who is the culprit – the virus or the anti-virus?98
226  Reduced synaptic density in progressive supranuclear palsy and corticobasal syndrome, revealed by [11C]UCB-J PET92
Haemorrhagic myelitis as a manifestation of MOG antibody-associated disease84
35 Processing speed (PS) improvement in alcohol related brain damage (ARBD)82
Navigating the presymptomatic frontier in genetic ALS and FTD77
086 Long-term efficacy of fremanezumab in migraine patients with inadequate response to prior preventive medication classes74
094  Measuring neutralising antibodies (NAbs) to interferon-beta (IFNB) for multiple sclerosis (MS): a neglected practice?74
099  Safety and effectiveness of dimethyl fumarate in multiple sclerosis patients treated over 5 years73
005  Infusion associated reactions in ocrelizumab-treated multiple sclerosis patients69
122  Neurological manifestations of haemophagocytic lymphohistiocytosis68
White matter hyperintensities and brain microbleeds in ataxia-telangiectasia: the Cambridge cohort64
102  The cost of misdiagnosis in POEMS syndrome64
001  Machine learning accurately determines the population prevalence of Alzheimer’s disease based on microbiome profile61
010  Safety and efficacy of long-term dimethyl fumarate treatment58
201  Management of an unusual presentation of spontaneous intracranial hypotension (SIH)56
184  Right data, right care54
L-arginine and mitochondrial encephalomyopathy, lactic acidosis and stroke- like episodes (MELAS): a systematic review53
238  Cogniton and mood disorder in cervical dystonia53
West is best – a strongman with numb feet52
164  Progressive multifocal leukoencephalopathy (PML) following autologous periph- eral blood stem cell transplantation for multiple myeloma52
12 A pilot investigation of interoceptive accuracy, awareness, and sensibility in functional neurological disorder50
091  CIDP mimic in a patient with HIV; An unusual presentation of POEMS syndrome50
Genetics of validated Parkinson’s disease subtypes in the Oxford Discovery and Tracking Parkinson’s cohorts48
059 Cannabidiol in refractory adult epilepsies: broadening the Lennox-Gastaut phenotype?48
003  Neuroanatomical signatures of genetic risk for Alzheimer’s disease in healthy adults47
143  Catastrophising cognitions in patients with psychogenic non-epileptic seizures compared to patients with epilepsy46
114  Effect of siponimod on cognitive processing speed in SPMS patients with active and non-active disease46
Multiple sclerosis reactivations after fingolimod discontinuation for pregnancy planning45
Neural (re)organisation of language and memory: implications for neuroplasticity and cognition44
101 Motor and non-motor features of prodromal PD44
Sodium valproate is associated with cortical thinning of disease-specific areas in juvenile myoclonic epilepsy44
Brain atrophy rates vary with age in relapsing-remitting multiple sclerosis43
High frequency ofHTRA1ANDABCC6mutations in Japanese patients with adult-onset cerebral small vessel disease43
Improved naming in patients with Broca’s aphasia with tDCS41
Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis40
DNA methylation profiling in central nervous system tumours40
Environmental risk scores of persistent organic pollutants associate with higher ALS risk and shorter survival in a new Michigan case/control cohort40
Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis40
0.18213987350464